Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 8/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 5/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369571 | 0.85 | MAP2K4 (0.45) | MAP2K4KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL6375165 | 0.84 | PTGER1 (0.51) | MAP2K4CKS1BSKP1SKP2KDM4E | |
| SCHEMBL6370068 | 0.83 | MAP2K4 (0.48) | MAP2K4CKS1BSKP1SKP2KDM4E | |
| SCHEMBL6592464 | 0.80 | MAP2K4 (0.43) | MAP2K4KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL6370428 | 0.79 | MAP2K4 (0.47) | MAP2K4KDM4EPKMALDH1A1LMNA | |
| SCHEMBL1513048 | 0.78 | MAP2K4 (0.48) | MAP2K4CKS1BSKP1SKP2KDM4E | |
| SCHEMBL6369555 | 0.78 | MAPK8 (0.47) | MAP2K4PTGER1 | |
| SCHEMBL6370071 | 0.78 | MAP2K4 (0.46) | MAP2K4CKS1BSKP1SKP2KDM4E | |
| SCHEMBL6370616 | 0.78 | MAP2K4 (0.57) | MAP2K4PTGER1 | |
| SCHEMBL6370211 | 0.78 | MAP2K4 (0.44) | MAP2K4CKS1BSKP1SKP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | MAP2K4 2785/4885ACACB 4208/4885CKS1B 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.